Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis

NCT ID: NCT04984278

Last Updated: 2024-12-11

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 56 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-08-16
• Study Completion Date: 2022-11-11

Brief Summary

This study will be conducted to evaluate the effect of multiple doses of nabiximols compared with placebo on a clinical measure of velocity-dependent muscle tone in the lower limbs (Lower Limb Muscle Tone-6 [LLMT-6]) in participants with multiple sclerosis (MS). LLMT-6 is defined as the average of the 6 individual Modified Ashworth Scale (MAS)-transformed scores of knee flexors, knee extensors, and plantar flexors on both sides of the body.

Detailed Description

Each period of this multicenter, randomized, double-blind, placebo-controlled, 2-treatment, 2-period, crossover trial includes a 7-day Baseline period, a 3-week treatment period (comprising a 2-week titration phase and a 1-week maintenance phase).

Eligible participants will enter the 7-day baseline period of each treatment period. During baseline, participants will maintain their optimized oral MS antispasticity medication regimen and record their 11-point Numerical Rating Scale (NRS) spasticity score and spasm count using an electronic daily diary. On Day 1, eligible participants will be randomized to 1 of 2 treatment sequences, each composed of 2 treatment periods, with administration of multiple doses of nabiximols or placebo in a 1:1 ratio.

Participants will be advised to titrate the investigational medicinal product (IMP), beginning with 1 spray/day, to an optimized dose or to a maximum of 12 sprays/day over the first 14 days of treatment. Participants should continue at the same dose level achieved at the end of the titration phase ±1 spray divided into a morning dose and an evening dose for the remainder of the treatment period.

Lower limb muscle tone, health-related quality of life, safety, tolerability, and pharmacokinetics will be evaluated during the treatment period.

Participants who complete the trial will participate for a total of approximately 11 weeks (77 days), including the 7-day baseline period.

Conditions

Spasticity With Multiple Sclerosis

Keywords

multiple sclerosis; MS; spasticity; velocity-dependent muscle tone; nabiximols

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Nabiximols

Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides. Study dependent: Each spray delivers 100 microliters (μL) of nabiximols. A pre-determined number of sprays, but no less than 4 sprays, of nabiximols will be self-administered by participants as an oromucosal spray, under supervision of trial staff during 2 study visits to the trial site after they temporarily discontinued treatment with prescribed nabiximols (Sativex) as part of their regular medication.

Group Type: EXPERIMENTAL

Nabiximols

Intervention Type: DRUG

oromucosal spray

Placebo

Placebo to match nabiximols is presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray delivers 100 μL containing no active ingredients.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

oromucosal spray

Interventions

Nabiximols

oromucosal spray

Intervention Type: DRUG

Placebo

oromucosal spray

Intervention Type: DRUG

Other Intervention Names

GW-1000-02; Sativex

Eligibility Criteria

Inclusion Criteria

Screening (Visit 1)

• Willing and able to give informed consent for participation in the trial
• Willing and able (in the investigator's opinion) to comply with all trial requirements
• Has had a diagnosis with any disease subtype of multiple sclerosis (MS), by revised 2017 McDonald criteria, for at least 12 months prior to Visit 1 (Screening) and is expected to remain stable for the duration of the trial
• Has an Modified Ashworth Scale (MAS) untransformed score of at least 2 in 2 or more of 6 muscle groups (right knee flexors, left knee flexors, right knee extensors, left knee extensors, right plantar flexors, or left plantar flexors) at Visit 1 (Screening)
• If currently receiving approved anti-spasticity therapy, it must be with a stable dosing regimen for at least 30 days prior to Visit 1 (Screening). The participant must be willing to maintain the same antispasticity medication and not plan to initiate a new course of physiotherapy for the duration of the trial.
• If currently receiving an approved MS disease-modifying therapy, it must be at a stable dose for at least 3 months prior to Visit 1 (Screening) and be expected to remain stable for the duration of the trial.
• If currently receiving dalfampridine or fampridine, it must be at a stable dose for at least 3 months prior to Visit 1 (Screening) and is expected to remain stable for the duration of the trial.

• Completed at least 5 of 7 days of their electronic diary reporting during the 7 days immediately preceding Visit 2 (Day 1)

Exclusion Criteria

• Has taken nabiximols, cannabis, or a cannabis-derived product for medicinal or recreational purposes in the 30 days prior to Visit 1 (Screening) or unable to abstain for the duration of the study
• Did not tolerate or did not respond adequately to treatment with nabiximols or another cannabis-based medication if exposed at any time before the 30-day period prior to Visit 1 (Screening)
• Any concomitant disease or disorder that has spasticity-like symptoms or that may influence the participant's level of spasticity
• Medical history suggests that relapse/remission is likely to occur during the trial, which, in the opinion of the investigator, is expected to influence the participant's spasticity
• Has had a relapse of MS within the 60 days prior to Visit 1 (Screening)
• Currently using botulinum toxin injection for the relief of spasticity (within 6 months of Visit 1 [Screening]) or is unwilling to abstain for the duration of the trial
• Currently taking antipsychotic medication
• Currently taking benzodiazepines unless doses and dosing regimen have been stable for at least 30 days prior to Visit 1 (Screening)
• Clinically suspected to have a contracture in one of the muscle groups of the lower limbs, preventing assessment with the MAS
• Has any known or suspected hypersensitivity to cannabinoids or any of the excipients of the investigational medicinal product (IMP)
• Male and fertile (i.e., after puberty unless permanently sterile by bilateral orchiectomy) unless willing to ensure that he uses male contraception (condom or vasectomy) or remains sexually abstinent during the trial and for 3 months thereafter
• Female and of childbearing potential (i.e., following menarche and until becoming postmenopausal for ≥ 12 consecutive months unless permanently sterile by hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) unless willing to ensure that she uses a highly effective method of birth control (e.g., intrauterine device/hormone-releasing system, bilateral tubal occlusion, vasectomized partner, or sexual abstinence) during the trial and for 3 months thereafter. Participants using combined hormonal methods or a progestogen-only pill or injection or implant should use an additional barrier method such as a male condom or diaphragm during the trial and for 3 months thereafter.
• Female and pregnant (positive pregnancy test at Visit 1 [Screening] or Visit 2 [Day 1]), lactating, or planning pregnancy during the course of the trial or within 3 months thereafter.
• Has received an IMP within the 30 days prior to Visit 1 (Screening)
• Has any other clinically significant disease or disorder (including seizure disorder) that, in the opinion of the investigator, may put the participant, other participants, or site staff at risk because of participation in the trial, influence the interpretation of trial results, or may affect the participant's ability to take part in the trial
• Has any abnormalities identified following a physical examination, clinical laboratory, serology, or other applicable screening procedures that, in the opinion of the investigator, would jeopardize the safety of the participant or the conduct of the study if he or she took part in the trial
• Has any history of suicidal behavior in the 5 years prior to Visit 1 (Screening) or a score of 3, 4, or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the month prior to Visit 1 (Screening)
• Has any known or suspected history of alcohol or substance abuse (including opiate abuse) or dependence within 1 year prior to Visit 1 (Screening)
• Currently using an illicit drug or current nonprescribed use of any prescription drug
• Has a history of psychiatric or neurologic disorder that, in the opinion of the investigator, may interfere with trial participation, data interpretation, or conduct of trial procedures
• Has a history of severe psychiatric disorder that may be exacerbated by the use of a cannabinoid-containing product
• Has any planned clinical interventions or intends to change any or all medications that may have an effect on spasticity or MS during the trial
• Currently taking drugs that are solely metabolized by UGT1A9 and UGT2B7
• Currently taking strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, phenobarbital, St. John's Wort)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Jazz Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Mountain View Clinical Research

Denver, Colorado, United States

Collier Neurologic Specialists

Naples, Florida, United States

University of South Florida

Tampa, Florida, United States

Consultants in Neurology - Northbrook

Chicago, Illinois, United States

Premier Neurology Research, PC

Greer, South Carolina, United States

Neurology Clinic-Cordova

Cordova, Tennessee, United States

NeuropsychiatrieHK

Choceň, , Czechia

NeuropsychiatrieHK

Hradec Králové, , Czechia

Krajská Zdravotní - Nemocnice Teplice

Teplice, , Czechia

Niepubliczny Zakład Opieki Zdrowotnej NEURO - KARD

Poznan, Greater Poland Voivodeship, Poland

Centrum Medyczne Neuromed - Ośrodek Badań Klinicznych

Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

Małopolskie Centrum Kliniczne

Krakow, Lesser Poland Voivodeship, Poland

Instytut Zdrowia dr Boczarska-Jedynak

Oświęcim, Lesser Poland Voivodeship, Poland

Indywidualna Praktyka Lekarska Dr Hab Konrad Rejdak

Lublin, Lublin Voivodeship, Poland

Centrum Medyczne Pratia - Warszawa

Warsaw, Masovian Voivodeship, Poland

Szpital Wolski im dr. Anny Gostyńskiej Samodzielny Publiczny Zakład Opieki Zdrowotnej

Warsaw, Masovian Voivodeship, Poland

MA-LEK A.M. Maciejowscy S.C. Centrum Terapii SM

Katowice, Silesian Voivodeship, Poland

DENDRYT Centrum Medyczne

Katowice, Silesian Voivodeship, Poland

Neuro-Medic Janusz Zbrojkiewicz

Katowice, Silesian Voivodeship, Poland

Wielospecjalistyczne Centrum Medyczne Ibismed

Zabrze, Silesian Voivodeship, Poland

RESMEDICA Poradnia Neurologiczna

Kielce, Świętokrzyskie Voivodeship, Poland

Hospital Universitario de Getafe

Getafe, Madrid, Spain

Institut Hospital del Mar d'Investigacions Mèdiques

Barcelona, , Spain

Hospital Universitario Ramón y Cajal

Madrid, , Spain

Hospital Vithas Nisa Sevilla

Seville, , Spain

Panthera Biopartners - North London

North London, England, United Kingdom

ReCognition Health - Plymouth

Plymouth, England, United Kingdom

Panthera Biopartners - Preston

Preston, England, United Kingdom

Sheffield Teaching Hospitals NHS Foundation Trust

Sheffield, England, United Kingdom

NHS Highland

Inverness, Scotland, United Kingdom

Countries

United States; Czechia; Poland; Spain; United Kingdom

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

2020-003271-18

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

GWSP20105

Identifier Type: -

Identifier Source: org_study_id